Advertisement

Topics

[Comment] Insulin signalling: new target for Parkinson's treatments?

19:59 EDT 3 Aug 2017 | The Lancet

Parkinson's disease is the second most common neurodegenerative disease, and affects 2–3% of people aged 65 years and older.1 The number of affected people is expected to double between 2005 and 2030 as the world's population ages, which will further increase the societal and economic burdens of the disease.1 Although in the past 20 years understanding of the molecular mechanisms underlying neuronal dysfunction and cell death in Parkinson's disease has improved substantially and novel therapeutic targets have been identified, no treatments with proven disease-modifying efficacy have become available.

Original Article: [Comment] Insulin signalling: new target for Parkinson's treatments?

NEXT ARTICLE

More From BioPortfolio on "[Comment] Insulin signalling: new target for Parkinson's treatments?"

Quick Search
Advertisement
 

Relevant Topic

Parkinson's Disease
Parkinson's is a progressive neurological condition, affecting one person in every 500, 95% of which are over 40. It is caused by degeneration of more than 70% of the substantia nigra, which depletes the dopamine (the neurotransmitter involved in pro...